October 3rd 2023
Integrating clinical data parameters along with chest X-ray findings, the multimodal artificial intelligence (AI) model outperformed the use of clinical parameters only and chest X-rays only for various conditions ranging from congestive heart failure and chronic kidney disease to hypertension and pneumonia.
September 22nd 2023
In a multicenter study examining four commercially available artificial intelligence (AI) software products for chest X-rays in over 2,000 patients, researchers found sensitivity rates ranging between 33 to 61 percent for vague airspace disease and 9 to 94 percent for small pneumothorax and pleural effusion.
In thie upcoming program, Drs Umesh Oza and Jaideep S. Sohi, will explore recent PSMA-PET imaging advancements in prostate cancer, focusing on clinical utility and guideline driven recommendations.
Researchers noted a 20.1 percent incidence of bone-only metastasis in a cohort of men with castration-resistant prostate cancer, according to findings from research presented at the recent Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.
For patients discharged from the hospital with confirmed COVID-19, median five-month follow-up MRI findings revealed a greater likelihood of regional brain volume reduction, parenchymal lung abnormalities and loss of corticomedullary differentiation in the kidney in comparison to people who have not had COVID-19.
Thirty-five percent of the interventional radiology malpractice cases involved vascular procedures and 26 percent of overall malpractice cases that went to trial resulted in plaintiff judgments with the average award being over $2 million.
The transitional pass-through payment reimbursement code for the FDA-approved PSMA PET agent for prostate cancer detection will be effective as of October 1, according to the Centers for Medicare and Medicare Services (CMS).
For patients who had previous radiotherapy for prostate cancer (PCa), researchers found that a biparametric MRI-based deep learning model demonstrated an 81.5 percent sensitivity rate for PCa recurrence in patients previously treated with external beam radiation treatment (EBRT) and 100 percent sensitivity in patients with greater than 34 ml in gland volumes.
The Pulmonary Embolism (PE) Triage and Notification (PETN) module with RapidAI’s RapidPE platform reportedly demonstrated over 90 percent sensitivity and specificity rates for detection of central PE on computed tomography (CT), according to multicenter study findings presented at the 9th Annual Pulmonary Embolism Symposium.